Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 26 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Under the programme initiated 7 August 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 7 August 2024 to 4 November 2024.

Since the announcement 19 August 2024, the following transactions have been made:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 335,187   298,612,988
19 August 2024 41,000 914.27 37,485,049
20 August 2024 41,000 912.57 37,415,485
21 August 2024 41,000 908.38 37,243,653
22 August 2024 41,000 919.59 37,703,009
23 August 2024 41,000 915.58 37,538,885
Accumulated under the programme 540,187   485,999,068

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 12,935,944 B shares of DKK 0.10 as treasury shares, corresponding to 0.3% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 23 August 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 11,607,313 B shares at an average share price of DKK 879.94 per B share equal to a transaction value of DKK 10,213,705,118.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
        

Contact for further information.

Media:  
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com

Investors:  
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Sina Meyer
+45 3079 6656
azey@novonordisk.com

Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com
Ida Schaap Melvold
+45 3077 5649 idmg@novonordisk.com

Company announcement No 66/2024

Attachments

  • CA242608-share-repurchase
  • 20242608 safe harbour transaction details

Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De Oct 2024 a Oct 2024 Haga Click aquí para más Gráficas Novo Nordisk.
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024 Haga Click aquí para más Gráficas Novo Nordisk.